Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.88 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.88 |
| ▸ | PGR | P06401 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | SHBG | P04278 | 2/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL29829445 | 0.95 | HIF1A (0.94) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL5699764 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL10261067 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL6932400 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL13046615 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL24900238 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL10292969 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL6370134 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL15114813 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 | |
| Hydrocortisone SCHEMBL13202859 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10NR3C1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118760-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2024-06-06 | — | — | WO | claimed |
| CN-117042804-A | Peptide-linked drug delivery system | 康奈尔大学 | 2023-11-10 | — | — | CN | claimed |
| EP-4262880-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | Cornell University (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230190948-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERISTY | 2023-06-22 | — | — | US | claimed |
| US-20230001003-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | HOPE CITY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022140289-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2022-06-30 | — | — | WO | claimed |
| US-11246942-B2 | Meditopes and meditope-binding antibodies and uses thereof | CITY OF HOPE (US) | 2022-02-15 | — | — | US | claimed |
| US-11179476-B2 | Enzyme-responsive peptide nanofiber compositions and uses thereof | CORNELL UNIVERSITY (US) | 2021-11-23 | — | — | US | claimed |
| US-20200108156-A1 | ENZYME-RESPONSIVE PEPTIDE NANOFIBER COMPOSITIONS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2020-04-09 | — | — | US | claimed |
| US-10449259-B2 | Enzyme-responsive peptide nanofiber compositions and uses thereof | CORNELL UNIVERSITY (US) | 2019-10-22 | — | — | US | claimed |
| US-20180296697-A1 | ENZYME-RESPONSIVE PEPTIDE NANOFIBER COMPOSITIONS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-18 | — | — | US | claimed |
| US-20180193479-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | MEDITOPE LLC | 2018-07-12 | — | — | US | claimed |
| US-20160201059-A1 | RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC DELIVERY TO PANCREATIC CANCER CELLS | HOPE CITY (US) | 2016-07-14 | — | — | US | claimed |
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024118760-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3889182-B1 | ANTIGEN BINDING CONSTRUCTS TO CD8 | IMAGINAB INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20120087860-A1 | METHODS FOR IN VIVO CANCER DETECTION, DIAGNOSIS AND THERAPY USING MULTIDOMAIN BIOTAGS | MALECKI MAREK (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120083761-A1 | METHODS FOR SELECTIVE ERADICATION OF METASTASIZING CANCER CELLS EX VIVO USING MULTIDOMAIN BIOTAGS | MALECKI MAREK (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083005-A1 | METHODS FOR IN VITRO CANCER CELL DETECTION, DIAGNOSIS AND THERAPY USING MULTIDOMAIN BIOTAGS | MALECKI MAREK (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110268656-A1 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE | NORGINE VENTURES FUND I S.C.A. SICAR (LU) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | CTSA, GZMB, PRF1 | NR3C1 4542/4885HIF1A 1099/4885HSD17B10 4097/4885 |
| US-20180193479-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | FCGR3B, FCGR2A, FCGR1A | NR3C1 838/4885HIF1A 1534/4885HSD17B10 4619/4885 |
| US-11246942-B2 | Meditopes and meditope-binding antibodies and uses thereof | FCGR3B, FCGR2A, FCGR1A | NR3C1 838/4885HIF1A 1534/4885HSD17B10 4619/4885 |
| US-20180296697-A1 | ENZYME-RESPONSIVE PEPTIDE NANOFIBER COMPOSITIONS AND USES THEREOF | RNASE1, IAPP, DNPEP | NR3C1 4810/4885HIF1A 1140/4885HSD17B10 2224/4885 |
| US-10449259-B2 | Enzyme-responsive peptide nanofiber compositions and uses thereof | RNASE1, IAPP, DNPEP | NR3C1 4810/4885HIF1A 1140/4885HSD17B10 2224/4885 |
| US-20230190948-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | GLS, AGBL2, ATP6V1B1 | NR3C1 3950/4885HIF1A 1891/4885HSD17B10 3417/4885 |
| US-11179476-B2 | Enzyme-responsive peptide nanofiber compositions and uses thereof | RNASE1, IAPP, DNPEP | NR3C1 4810/4885HIF1A 1140/4885HSD17B10 2224/4885 |
| US-20200108156-A1 | ENZYME-RESPONSIVE PEPTIDE NANOFIBER COMPOSITIONS AND USES THEREOF | RNASE1, IAPP, DNPEP | NR3C1 4810/4885HIF1A 1140/4885HSD17B10 2224/4885 |
| US-20230001003-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | FCGR3B, FCGR2A, FCGR1A | NR3C1 838/4885HIF1A 1534/4885HSD17B10 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.